Press Release

Invasive Fungal Infection Market to grow with a CAGR of 3.80%

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Invasive Fungal Infection Market.

 

According to TechSci Research report, “Global Invasive Fungal Infection Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Invasive Fungal Infection Market has valued at USD 6.99 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.80% through 2028.   This can be due to collaborations and partnerships among leading companies with a diverse approach to merge the expertise of individual companies and to strengthen their position in the market.

Increased awareness plays a crucial role in driving the demand for treatments and diagnostics in the Global Invasive Fungal Infection Market. Greater awareness among healthcare professionals and the public about the signs, symptoms, and risk factors of invasive fungal infections leads to earlier detection and diagnosis. This results in more patients seeking medical attention when they experience symptoms, allowing for timely treatment and better outcomes. Awareness campaigns and education efforts can encourage healthcare providers to incorporate fungal infection screening into their routine practice, especially for high-risk patient populations. This proactive approach to screening helps identify infections before they become severe. Heightened awareness often drives investment in research and development of advanced diagnostic methods for invasive fungal infections. As a result, more accurate and rapid diagnostic tools become available, aiding in early detection and targeted treatment. In some cases, fungal infections may be stigmatized or overlooked, leading to delayed diagnosis and treatment. Increased awareness helps reduce the stigma associated with these infections, encouraging individuals to seek medical help without hesitation. Educated patients are more likely to engage in their healthcare and advocate for their own well-being. Increased awareness empowers patients to recognize the importance of timely diagnosis and treatment, leading to better adherence to prescribed therapies.

Invasive fungal infections (IFIs) are severe and potentially lethal infections resulting from fungi infiltrating deep tissues, organs, or the bloodstream within the human body. These infections can manifest in individuals with compromised immune systems, such as those receiving chemotherapy or organ transplants, or individuals with specific medical conditions like diabetes or HIV/AIDS.

In March 2023, GSK plc and SCYNEXIS, Inc. have recently formed an exclusive licensing agreement for Brexafemme (ibrexafungerp tablets), an FDA-approved antifungal medication designed to address vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). Under this exclusive arrangement, GSK gains the rights to market Brexafemme for VVC and RVVC treatment while also continuing the development of ibrexafungerp. Ibrexafungerp is currently in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a severe and life-threatening fungal infection. In GSK's pipeline, infectious diseases and HIV research constitute a significant portion, comprising about two-thirds. Brexafemme aligns well with GSK's portfolio of first or best-in-class treatments, which includes late-stage antibiotics such as gepotidacin, a potential groundbreaking antibiotic for uncomplicated urinary tract infections (uUTI) - the first of its kind in over two decades, and tebipenem, a promising candidate for the treatment of complicated urinary tract infections (cUTI).

Limited treatment options are a significant challenge in the Global Invasive Fungal Infection Market. This challenge arises due to several factors, including the limited number of antifungal drug classes available, the emergence of antifungal resistance, and the complexity of managing fungal infections in certain patient populations. The number of antifungal drug classes available for the treatment of invasive fungal infections is relatively small compared to antibiotics or other classes of drugs. The main classes of antifungal agents include azoles, echinocandins, polyenes, and flucytosine. This limited arsenal of drugs makes it challenging to treat infections, especially when resistance to one or more drug classes emerges. The emergence of antifungal resistance, particularly among fungal species like Candida and Aspergillus, poses a serious threat to effective treatment. Resistance can develop due to factors such as overuse or inappropriate use of antifungal drugs, making it even more challenging to manage invasive fungal infections. Different fungal species have varying susceptibility to antifungal drugs. Choosing the right antifungal agent based on the specific fungal pathogen causing the infection is critical. In some cases, susceptibility testing is necessary to guide treatment decisions.

 

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Invasive Fungal Infection Market.”

 

Global Invasive Fungal Infection Market is segmented based on Disease Type, Drug Type, and by region.

Based on Disease Type, Global Invasive Fungal Infection Market is segmented into Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others. Cryptococcal meningitis is a severe fungal infection that affects the membranes covering the brain and spinal cord, known as the meninges. It is caused by the fungus Cryptococcus neoformans. This type of meningitis is considered an opportunistic infection, meaning it typically occurs in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or individuals undergoing immunosuppressive therapy. Individuals with compromised immune systems are at the highest risk of developing cryptococcal meningitis. This includes people with advanced HIV/AIDS, those on immunosuppressive medications (such as after organ transplantation or for autoimmune diseases), and individuals with certain cancers. Cryptococcus neoformans typically enter the body through inhalation of fungal spores present in the environment. Once in the lungs, the fungus can disseminate through the bloodstream to the central nervous system (CNS), leading to meningitis. The symptoms of cryptococcal meningitis can be like those of other types of meningitis and may include fever, headache, stiff neck, nausea, vomiting, and altered mental status. Neurological symptoms may also occur, such as confusion, seizures, and vision changes.

Based on Region, North America held the largest share in the Global Invasive Fungal Infection Market. North America has one of the highest healthcare spending rates in the world. This allows for the adoption of advanced medical technologies and therapies, including the latest antifungal treatments, to manage invasive fungal infections effectively. Many clinical trials for antifungal drugs are conducted in North America, which not only advances medical knowledge but also provides patients with access to cutting-edge treatments. Healthcare providers and the public in North America generally have a high level of awareness regarding fungal infections, which promotes early diagnosis and appropriate treatment.

 

Some of the major companies operating in the Global Invasive Fungal Infection Market include:

  • Cidara Therapeutics, Inc.
  • Basilea Pharmaceutica AG Allschwil
  • Pfizer Inc.
  • GlaxoSmith Kline
  • Bayer AG
  • Abbott Laboratories Ltd.
  • Merck & Co, Inc.
  • Astellas Pharma Inc.
  • Scynexis Inc.
  • Matinas BioPharma Holdings, Inc

 

Download Free Sample Report

Customers can also request 10% free customization on this report.

 

“Certain areas, particularly in North America, are projected to exert significant demand for the treatment of Invasive Fungal Infections. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Invasive Fungal Infection Market in the forecast period," said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Invasive Fungal Infection Market by Disease Type (Candidaemi Caa and Invasive Candiasis, Intra-abdominal Candiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Others), by Drug Type (Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Invasive Fungal Infection Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Invasive Fungal Infection Market.

 

 

Contact

Mr. Ken Mathews

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170                   

Tel: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant News